Navigation Links
Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study
Date:8/13/2009

FORT LAUDERDALE, Fla., Aug. 13 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that it has been selected by a leading European based Contract Research Organization (CRO) to provide eClinical solutions for a pivotal Phase III study in rheumatoid arthritis (RA). Phase III clinical studies serve to establish the safety and efficacy of investigational new drugs, in large patient populations, and are the last step prior to review for approval by the regulatory authorities, such as FDA and the EMEA . This particular RA study is expected to last 48 months and enroll close to 300 patients in 20 sites located in Europe.

"We are very excited to be working again with this leading CRO on this pivotal study," commented Stephen Johnson, OmniComm's COO. "We appreciate their ongoing trust in us and will continue to deliver superior products and services to them. We are also very excited about our continued expansion into the European marketplace. We have recently opened up another office in the United Kingdom, OmniComm Ltd., which will allow us to broaden our service and support offering even further." OmniComm Systems also has international offices in Bonn, Germany and Tula, Russia.

.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    CONTACT:   Stephen Johnson at: + 1 954-377-1726

               Catherine Lemercier
               OmniComm Systems, Inc
               954-473-1254 Extension 283
               clemercier@omnicomm.com

               Gary Nash
               CEOcast, Inc. for OmniComm
               212-732-4300
               gnash@ceocast.com


'/>"/>
SOURCE OmniComm Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading
2. Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services
3. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
4. OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.
5. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
6. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
7. Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration
8. Leading for Growth in the New Economic Reality Includes Vision and Innovation
9. National Institutes of Health Join Nations Leading Postgrad Bio Jobs Board
10. The World's Leading IP Strategists Revealed
11. PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  If only ... tumor had a mutation-conferring resistance to chemotherapy, thousands ... genomics research has focused on finding these mutations ... even from circulating tumor DNA in blood — ... oncology therapeutics. Unfortunately, however, detecting these ...
(Date:2/16/2017)... , ... February 16, 2017 , ... EIT Digital ... primarily aimed at the agricultural industry. Pilot studies are about to get under way ... IoT, Big Data and 5G innovations. The concept is expected to be transferred eventually ...
(Date:2/16/2017)... MENLO PARK, Calif. and ... -- Longitude Capital, a private investment firm focused on ... today announced the promotion of Josh Richardson ... Richardson focuses on investments in biotechnology companies.  He ... and has played important roles in Longitude,s investments ...
(Date:2/16/2017)... Feb. 16, 2017 Research and ... Biology: Global Markets" report to their offering. ... ... genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, ... assembly, genome editing, bioinformatics and specialty media) and enabled ...
Breaking Biology Technology:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):